Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia

PLoS One. 2017 May 18;12(5):e0177436. doi: 10.1371/journal.pone.0177436. eCollection 2017.

Abstract

Objectives: This study aims to assess the value for money and budget impact of offering hemodialysis (HD) as a first-line treatment, or the HD-first policy, and the peritoneal dialysis (PD) first policy compared to a supportive care option in patients with end-stage renal disease (ESRD) in Indonesia.

Methods: A Markov model-based economic evaluation was performed using local and international data to quantify the potential costs and health-related outcomes in terms of life years (LYs) and quality-adjusted life years (QALYs). Three policy options were compared, i.e., the PD-first policy, HD-first policy, and supportive care.

Results: The PD-first policy for ESRD patients resulted in 5.93 life years, equal to the HD-first policy, with a slightly higher QALY gained (4.40 vs 4.34). The total lifetime cost for a patient under the PD-first policy is around 700 million IDR, which is lower than the cost under the HD-first policy, i.e. 735 million IDR per patient. Compared to supportive care, the incremental cost-effectiveness ratio of the PD-first policy is 193 million IDR per QALY, while the HD-first policy resulted in 207 million IDR per QALY. Budget impact analysis indicated that the required budget for the PD-first policy is 43 trillion IDR for 53% coverage and 75 trillion IDR for 100% coverage in five years, which is less than the HD-first policy, i.e. 88 trillion IDR and 166 trillion IDR.

Conclusions: The PD-first policy was found to be more cost-effective compared to the HD-first policy. Budget impact analysis provided evidence on the enormous financial burden for the country if the current practice, where HD dominates PD, continues for the next five years.

MeSH terms

  • Cost-Benefit Analysis
  • Health Policy / economics*
  • Humans
  • Indonesia
  • Kidney Failure, Chronic / therapy*
  • Markov Chains
  • Renal Dialysis / economics*
  • Universal Health Insurance / economics*

Grants and funding

This work received funding support from the state budget from the Ministry of Health, Indonesia and the Australian Indonesian Partnership for Health Systems Strengthening (AIPHSS) under the Department of Foreign Affairs Trade, Australia. Technical assistance from the Health Intervention and Technology Assessment Program (HITAP) International Unit was supported by International Decision Support Initiative (iDSI) to provide technical assistance on health intervention and technology assessment to governments in low- and middle-income countries. iDSI is funded by the Bill & Melinda Gates Foundation, the UK's Department for International Development, and the Rockefeller Foundation. The HITAP team provided technical assistance to the authors throughout the conduct of the research, the writing of the report, and the publication process. The other funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.